Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.
How this was made
The 30-second read
Why it matters
The INI agreement is intended to produce real-world evidence comparing Nociscan chemical biomarker data with bone metabolic information from SPECT-CT, supporting more precise treatment decisions for chronic low back pain.
Market read
Aclarion is expanding Nociscan availability and setting up a real-world evidence study framework, which can improve adoption confidence but lacks immediate clinical/regulatory milestones in the release.
What to watch
Key missing details include study size, timelines, endpoints, and whether results will be used for reimbursement submissions or formal coverage discussions.
Background
Aclarion’s Nociscan is a SaaS platform using magnetic resonance spectroscopy-derived chemical biomarkers to identify painful lumbar discs, positioned alongside imaging like SPECT-CT.
Ticker impact
Aclarion announced an agreement to bring its Nociscan platform to the Institute of Neuro Innovation in Los Angeles for real-world evidence generation.
Near-term: modest positive bias for sentiment; follow-through depends on evidence outcomes and broader rollout.
The news is a commercial expansion and evidence-generation step (not a trial readout or reimbursement decision), so impact is likely incremental but directionally supportive.
Market effects
Reinforces the market’s emphasis on real-world evidence for diagnostic/biomarker platforms and MRI-adjacent SaaS workflows.
Greater Los Angeles clinic network expansion may accelerate local adoption and data capture.
If replicated, the RWE approach could strengthen global payer/provider confidence in biomarker-guided spine care.
Counterpoint
Real-world evidence generation does not guarantee reimbursement or clinical guideline adoption; outcomes may take longer than the market expects.
Key entities
- public_companyAclarion, Inc.
Commercial-stage healthcare technology company developing the Nociscan SaaS platform for chronic low back pain diagnostics.
- clinicInstitute of Neuro Innovation (INI)
Los Angeles clinic focused on research, innovation, and applied neuroscience; will host Nociscan for RWE generation.
- personAmir Vokshoor, MD
Neurosurgeon and founder of INI leading the multidisciplinary team for the proposed evidence work.
